GSK3 is a regulator of RAR-mediated differentiation

Leukemia

Volumn 26, Issue 6, 2012, Pages 1277-1285

  Gupta, K ^a   Gulen, F ^b   Sun, L ^a   Aguilera, R ^a   Chakrabarti, A ^c   Kiselar, J ^a   Agarwal, M K ^c   Wald, D N ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Cleveland Leukemia Therapeutics   (United States)

Author keywords

AML; differentiation; retinoids

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; LUCIFERASES; MICE; MICE, NUDE; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSCRIPTIONAL ACTIVATION; TRETINOIN;

EID: 84862005911     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.2     Document Type: Article

References (29)

1. Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 2006; 43: 89-95.
2. Tallmann MS. Curative therapeutic approaches to APL. Ann Hematol 2004; 83 (Suppl 1): S81-S82.
3. Wald DN, Vermaat HM, Zang S, Lavik A, Kang Z, Peleg G et al. Identification of 6-benzylthioinosine as a myeloid leukemia differentiation- inducing compound. Cancer Res 2008; 68: 4369-4376.
4. Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth B, Agarwal M et al. Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One 2011; 6: e21203.
5. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-1209.
6. Holmes T, O'Brien TA, Knight R, Lindeman R, Shen S, Song E et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008; 26: 1288-1297.
7. Song EY, Palladinetti P, Klamer G, Ko KH, Lindeman R, O'Brien TA et al. Glycogen synthase kinase-3beta inhibitors suppress leukemia cell growth. Exp Hematol 2010; 38: 908-921 e901.
8. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156: 885-898.
9. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116 (Part 7): 1175-1186. (Pubitemid 36410657)
10. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426. (Pubitemid 32781670)
11. Hernandez F, Nido JD, Avila J, Villanueva N. GSK3 inhibitors and disease. Mini Rev Med Chem 2009; 9: 1024-1029.
12. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008; 11: 533-543. (Pubitemid 351950847)
13. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007; 110: 4436-4444. (Pubitemid 351377810)
14. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 2008; 49: 1945-1953.
15. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28: 773-796.
16. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 1979; 149: 969-974. (Pubitemid 9154758)
17. Newburger PE, Chovaniec ME, Greenberger JS, Cohen HJ. Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 1979; 82: 315-322. (Pubitemid 9241098)
18. Collins SJ, Bodner A, Ting R, Gallo RC. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by componuds which induce differentiation of murine leukemia cells. Int J Cancer 1980; 25: 213-218. (Pubitemid 10217394)
19. Guglielmo P, Pagano MC, Giustolisi R. [The nitroblue tetrazolium activated test in the study of granulocytic function. Proposed methodology]. Boll Soc Ital Biol Sper 1980; 56: 183-187.
20. Newburger PE, Speier C, Borregaard N, Walsh CE, Whitin JC, Simons ER. Development of the superoxide-generating system during differentiation of the HL-60 human promyelocytic leukemia cell line. J Biol Chem 1984; 259: 3771-3776. (Pubitemid 14173417)
21. Prakash R. A review of the hematologic side effects of lithium. Hosp Community Psychiatry 1985; 36: 127-128. (Pubitemid 15126318)
22. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 1998; 95: 8363-8368. (Pubitemid 28326118)
23. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidencebased approach. Part II: clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331-349.
24. MacAulay K, Blair AS, Hajduch E, Terashima T, Baba O, Sutherland C et al. Constitutive activation of GSK3 down-regulates glycogen synthase abundance and glycogen deposition in rat skeletal muscle cells. J Biol Chem 2005; 280: 9509-9518. (Pubitemid 40409646)
25. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007; 61: 216-222. (Pubitemid 46072775)
26. Si J, Mueller L, Collins SJ. GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells. Leukemia 2011; 25: 1914-1918.
27. Farboud B, Privalsky ML. Retinoic acid receptor-alpha is stabilized in a repressive state by its C-terminal, isotype-specific F domain. Mol Endocrinol 2004; 18: 2839-2853. (Pubitemid 39577910)
28. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010; 62: 1285-1298.
29. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24: 201-221. (Pubitemid 38938791)